Circulating endothelial cell (CEC) monitoring in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line bevacizumab (BEV)-based combination regimens: Results of the randomized phase II FNCLCC-ACCORD 13/0503 trial

Françoise Farace,Jean Mendiboure,Antoine Adenis,Eveline Boucher,J-Y Pierga,T. Conroy,C. Montoto-Grillot,J. Pignon,Michel Ducreux,D. Malka,Fnclcc

Circulating endothelial cell (CEC) monitoring in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line bevacizumab (BEV)-based combination regimens: Results of the randomized phase II FNCLCC-ACCORD 13/0503 trial

2009

Françoise Farace
Jean Mendiboure
Antoine Adenis
Eveline Boucher
J-Y Pierga
T. Conroy
C. Montoto-Grillot
J. Pignon
Michel Ducreux
D. Malka
Fnclcc

4071 Background: There is no validated biomarker to predict the efficacy of BEV, an anti-VEGF monoclonal antibody. Rare cell subpopulations such as CEC are good candidates. Methods: Pts with mCRC, ...

Keywords:

Circulating endothelial cell
Bevacizumab
Colorectal cancer
Cancer research
Intensive care medicine
Medicine
first line
Internal medicine
Oncology

Correction
Cite
Save
Machine Reading By IdeaReader

References

Citations